To include your compound in the COVID-19 Resource Center, submit it here.

Medivir rises on Phase IIa OA data

Medivir AB (SSE:MVIR B) gained SEK14.75 (25%) to SEK74.75 on Tuesday after reporting that MIV-711 slowed the degenerative effects of moderate osteoarthritis

Read the full 224 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE